Abstract: We analyzed the HSCEI eligible universe for the upcoming May 2026 index review, forecasting two deletions and two inclusions based on mechanical rank boundaries. Sunny Optical (2382 HK, Combined MV Rank 64, MV12 HKD 75.3bn) and Haier Smarthome (6690 HK, Combined MV Rank 61, MV12 HKD 71.0bn) both breach the rank-60 exclusion threshold and are forecast to be removed. WuXi Biologics (2269 HK, Combined MV Rank 33, MV12 HKD 132.1bn) qualifies as a mandatory inclusion under the rank-40 rule, representing a first-time addition to the index. Hansoh Pharma (3692 HK, Combined MV Rank 44, MV12 HKD 205.3bn) is the expected buffer-zone fill, though its inclusion is contingent on maintaining its position as the highest-ranked non-constituent in the 41-60 band, with Akeso (9926 HK, rank 45) as the nearest displacement risk. Both Healthcare names are added, with the primary forecast risk being FAF estimation differences versus HSIL's published inputs, particularly for Hansoh where FFMV rank (60) is the binding factor.
CHINA SHENHUA ENERGY, CSPC Pharma, SINO BIOPHARMACEUTICAL, HUA HONG SEMICONDUCTOR, PSBC, INNOVENT BIOLOGICS, SENSETIME, LI AUTO, ZTO EXPRESS, WUXI BIOLOGICS, SHENZHOU INTERNATIONAL, PICC P&C, Sunny Optical, KE, CHINA PACIFIC INSURANCE, ENN ENERGY, CHINA RES BEER, BankComm, HANSOH PHARMACEUTICAL, CATL, Sinopec, BEONE MEDICINES, LAOPU GOLD, JD Health, HAIER SMART HOME, COLI, CHINA TELECOM, China Unicom, CHINA RESOURCES POWER, HORIZON ROBOTICS, XPENG, LENOVO, AKESO, CHINA CITIC BANK
Interested in the full report? Get in touch with our team.